Table 5.
Base case values of epidemiologic parameters in cost-effectiveness studies of routine testing for Lynch Syndrome (LS) in patients with colorectal cancer (CRC) that relate to asymptomatic mutation carriers.
| Study | # Relatives Tested per Proband | % Relatives Testing Positive for Mutation | Uptake of Prevention among Mutation Carriers | Reduction in risk of CRC with LS Surveillance | Weighted Incidence of First CRC in Absence of Adherence to Prevention | Difference in Case-Fatality Rate of CRC in LS Relative to Non-LS Patients in Absence of Prevention |
|---|---|---|---|---|---|---|
| Mvundura et al. [32] | 2.1 | 45% | 79% | 62% | 41.3%—unadjusted | 24% |
| Ladabaum et al. [31] & Wang et al. [33] | 4 | 50% | 80% | 58% | 46%–54% by age 70 | 25%–30% |
| Sie et al. [34] | 8 | 39% | 88% | 63% | 3.5% per year | NR |
| Snowsill et al. [29,35] | 2.1 | 44% | 80% | 61% | 43.5%–46.4% | 21% |
| Severin et al. [14] | 1.1 | 50% | 81.8% | 52% | 42%—unadjusted 35.6%—adjusted | 33% |
| Barzi et al. [30] | 2.6 | Not stated | 60%–80% | 56% | 46%–54% by age 70 | NR |
NR: Not reported.